Am J Cardiol:部分患者CABG术后没能按照指南推荐服药

2016-05-31 Mechront 译 MedSci原创

根据发表在美国心脏病学杂志数据,近一半的患者接受CABG后,没有采取必要的他汀类药物和阿司匹林治疗。美国心脏协会科学声明建议CABG后使用他汀类药物和阿司匹林作为二级预防长期使用。托马斯杰斐逊大学的Michael P. Savage博士和同事对381名接受诊断性心导管检查术的患者的数据进行了回顾性分析,患者平均年龄69岁,其中男性占78%。数据显示,导管检查时67%的患者服用他汀类药物,75%的患

根据发表在美国心脏病学杂志数据,近一半的患者接受CABG后,没有采取必要的他汀类药物和阿司匹林治疗。

美国心脏协会科学声明建议CABG后使用他汀类药物和阿司匹林作为二级预防长期使用。

托马斯杰斐逊大学的Michael P. Savage博士和同事对381名接受诊断性心导管检查术的患者的数据进行了回顾性分析,患者平均年龄69岁,其中男性占78%。

数据显示,导管检查时67%的患者服用他汀类药物,75%的患者服用阿司匹林,还有52%的患者两种药物均在服用。此外还有21%的患者服用阿司匹林加氯吡格雷;没有服用他汀药物与服药者相比,LDL ≥ 100mg/dl的比例分别为53%和26%(P < .001)。

明显的隐静脉移植在他汀治疗和没有使用他汀治疗的患者中分别有26%和25%(P = .867);整体移植在两组中分别有46%和43%(P = .517)。阿司匹林的使用并没有影响移植血管通畅或血管造影状态。服用阿司匹林的患者中,46%进行了移植,30%的病变和24%的闭塞,42%的移植隐静脉。

PCI或重复CABG血运重建在他汀组合非他汀组分别为62%和55%(P = .224);阿司匹林组和非阿司匹林组分别为62%和55%(P = .361)。

Savage说,“我们的研究证实了,患者在术后长期随访过程中,服用阿司匹林和他汀类药物明显不足。不管是患者还是医护人员,还需要努力。”

原始出处:

Curl K, et al. Frequency of Use of Statins and Aspirin in Patients With Previous Coronary Artery Bypass Grafting.Am J Cardiol. 2016; doi:10.1016/j.amjcard.2016.04.006.

Many patients skip recommended medications after CABG.Healio.May 31, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781708, encodeId=5f4e1e817082d, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 05 20:39:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88055, encodeId=1c8e88055b5, content=要多宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:37:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87980, encodeId=e4ee8e980dd, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87952, encodeId=14378e9527e, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:42:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87951, encodeId=4f938e95164, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781708, encodeId=5f4e1e817082d, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 05 20:39:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88055, encodeId=1c8e88055b5, content=要多宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:37:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87980, encodeId=e4ee8e980dd, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87952, encodeId=14378e9527e, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:42:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87951, encodeId=4f938e95164, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 沉心多思

    要多宣传

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1781708, encodeId=5f4e1e817082d, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 05 20:39:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88055, encodeId=1c8e88055b5, content=要多宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:37:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87980, encodeId=e4ee8e980dd, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87952, encodeId=14378e9527e, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:42:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87951, encodeId=4f938e95164, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 1dd8c52fm63(暂无匿称)

    了解一下!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1781708, encodeId=5f4e1e817082d, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 05 20:39:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88055, encodeId=1c8e88055b5, content=要多宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:37:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87980, encodeId=e4ee8e980dd, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87952, encodeId=14378e9527e, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:42:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87951, encodeId=4f938e95164, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 milkshark

    值得研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1781708, encodeId=5f4e1e817082d, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Apr 05 20:39:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88055, encodeId=1c8e88055b5, content=要多宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Wed Jun 01 15:37:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87980, encodeId=e4ee8e980dd, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 01 07:34:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87952, encodeId=14378e9527e, content=值得研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:42:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87951, encodeId=4f938e95164, content=的确这样, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 01 06:41:00 CST 2016, time=2016-06-01, status=1, ipAttribution=)]
    2016-06-01 milkshark

    的确这样

    0

相关资讯

NEJM:远程缺血预处理不能改善CABG手术的临床疗效

远程缺血预处理(手臂的短暂性脑缺血和再灌注)能否提高接受冠状动脉旁路移植术(CABG)手术患者的临床疗效是不知道的。研究人员在一项随机试验中研究了这个问题。研究人员进行了一项多中心,假对照试验,涉及的参与者为使用血液心脏停搏正在接受体外循环CABG(有或无瓣膜手术)并处于手术风险增加的成年患者。麻醉诱导后和手术切口之前,患者被随机分配到接受远端缺血预处理(在上臂进行标准血压计4个5分钟的舒张和收缩

JACC:CABG术前血糖控制不良会出现不良预后

1型糖尿病(T1DM)患者发生心血管事件的风险很高。本研究旨在研究1型糖尿病患者CABG术前血糖控制不良是否会增加长期全因死亡及严重不良心血管事件(MACE)风险。 研究人员收纳了来自瑞典糖尿病研究注册中心的764名1型糖尿病患者。在平均4.7年的随访中,334名(44%)患者死亡或发生MACE事件(发病率:82/1000人/年)。调整多变量后,与对照组(HbA1c>7.0%)相比,1型糖尿病患

Circulation:CABG和PCI治疗血管病变或左心室收缩功能不全,孰优孰劣?

指南建议冠状动脉旁路移植术(CABG)对治疗多支血管病变和严重左心室(LV)收缩功能不全优于经皮冠状动脉介入治疗(PCI)。然而,在此类患者的随机试验中,还没有对CABG和PCI进行比较。该研究纳入了多支血管病变和LV收缩功能不全(射血分数≤35%)的患者,这些患者接受过依维莫司洗脱支架带(EES)的PCI或CABG,这些患者是从纽约州的注册中挑选出来的。主要成果是长期的全因死亡。次要终点为心肌梗

JACC:PCI和CABG治疗慢性肾脏疾病,长期和短期结果有差异

经皮冠状动脉介入治疗(PCI) vs 冠状动脉旁路移植术(CABG)的随机试验通常排除了患有慢性肾脏病(CKD)的患者。该研究的目的是评估CKD患者进行PCI vs CABG的结果。在纽约,该研究的参与者包括那些使用依维莫司洗脱支架接受PCI的CKD患者,以及倾向得分匹配的那些接受隔离CABG治疗多支冠状动脉病变的患者。主要研究终点为全因死亡率。次要终点是心肌梗死(MI),卒中和再次血运重建。在1

JACC:与PCI相比,CABG能够更大幅度的降低心梗有关的死亡率

在随机试验在,比较冠状动脉旁路移植术(CABG)和经皮冠状动脉介入治疗(PCI)的具体死因没有可用数据。

美国胸外科学会(AATS)首届国际冠脉外科大会撷英

         陈鑫教授 美国胸外科学会(AATS)首届国际冠脉外科大会(International coronarycongress,ICC)于2015年8月21~23日在纽约召开。本次大会由美国西奈山贝斯以色列医院普斯卡什(JohnPuskas)博士和英国牛津大学塔格特(David Tagga